| Document |
Document Title |
|
JP6306874B2 |
|
|
JP6305844B2 |
where R1 and R2 each represent a hydrogen atom or R1 and R2 form a benzene ring together with carbon atoms to which R1 and R2 are bonded, R3 represents a to straight-chain hydrocarbon group having 10 or more carbon atoms, and R4 represen...
|
|
JP2018505906A |
The present invention comprises an inhibitor of the Wnt signaling pathway of general formula (I) described and defined herein, a method of preparing the compound, an intermediate compound useful for the preparation of the compound, and a...
|
|
JP6281952B2 |
The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein ring A is substituted...
|
|
JP6276705B2 |
|
|
JP2017538711A |
Compounds that regulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods for synthesizing them, and methods for their therapeutic and / or prophylactic use are provided. Such compounds can be used alone, with incretin pep...
|
|
JP2017537193A |
The present invention provides a method for producing a polymer having at least one unit of the formula (1), and the production method is based on the formula (5) (Y in the above formula).2Is I, Br, Cl, or OS (O)2CF3The compound of formu...
|
|
JP6243056B2 |
Provided is a method for manufacturing 5-amino-3 substituted-1,2,4-thiadiazole, including a process of obtaining a compound represented by Formula (II) by adding a brominating agent and a base in this order to a mixture containing an alc...
|
|
JP6238942B2 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
JP6234340B2 |
The invention provides compounds which contain or are capable of producing a methylol molecule in an aqueous environment, for use in inducing apoptotic death of a neoplastic cell, inhibiting growth of an autologous neoplastic cell in a m...
|
|
JP6215229B2 |
Provided is a sulfonium salt compound represented by the following general formula (I): where R1 and R2 each denote the same or a different alkyl group having 1 to 18 carbon atoms, R3 and R4 each denote the same or a different alkyl grou...
|
|
JP6216326B2 |
A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
|
|
JP2017149953A |
To provide photo-stable highly luminescent chromophores of benzo heterocyclic systems useful in various applications, including wavelength conversion films having the potential to significantly enhance the solar harvesting efficiency of ...
|
|
JP6189324B2 |
The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resis...
|
|
JP6169100B2 |
N-arylamidine substituted trifluoroethyl sulfide derivatives (I) are new. N-arylamidine substituted trifluoroethyl sulfide derivatives of formula (I) are new. n : 0-2; either X1-X4 : cycloalkylalkyl, cycloalkyloxy, cycloalkyl-alkoxy, cyc...
|
|
JP6165744B2 |
The present disclosure describes new inhibitors or antagonists of Ras useful for the treatment of conditions resulting from Ras-induced or mediated cellular processes, including cellular proliferation, differentiation, apoptosis, senesce...
|
|
JP6158985B2 |
The present invention relates to an intermediate compound of modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"), compositions thereof which...
|
|
JP6154052B2 |
A method of producing a compound of formula (I) or a pharmacologically acceptable salt thereof, useful as a therapeutic agent and/or a preventive agent for pain or for a sodium channel associated disease: Ar 1 and Ar 2 : a heteroaryl gro...
|
|
JP2017516803A |
The present invention relates to sulfonamide derivatives, their use in medicine, compositions containing them, methods for their preparation, and intermediates used in such methods. More specifically, the present invention relates to a n...
|
|
JP6139682B2 |
The present invention relates to novel N-acylhydrazone derivatives, and more particularly to novel N-acylhydrazone derivatives having selective T cell inhibitory activity and/or anti-lymphoid malignancy activity, stereoisomers thereof, p...
|
|
JP2017081931A |
To provide antibacterial agents which can prevent infections cause by gram-negative bacteria, other compounds for use in the preparation of medicines and combinations of such compounds.The present invention provides a compound represente...
|
|
JP6129159B2 |
Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment...
|
|
JP2017511333A |
The present invention relates to the treatment or prevention of disorders associated with lamin A and / or lamin C deficiency or LMNA mutations, such as laminopathy, premature aging disorders, normal aging and cancer (such as cancer char...
|
|
JP2017511374A |
The present invention relates to drugs for preventing and treating RNA-containing viruses and diseases caused by DNA-containing viruses, and complications, and to prevent and treat diseases caused by RNA-containing viruses and DNA-contai...
|
|
JP6111195B2 |
The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The...
|
|
JP6099753B2 |
These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).
|
|
JP6095580B2 |
Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an...
|
|
JP2017039740A |
To provide novel (hetero)arylcyclopropylamine compounds, and their usage in therapy, including, e.g., treatment or prevention of cancer, a neurological disease or condition, or a viral infection.The invention provides compounds represent...
|
|
JP6080917B2 |
The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, n...
|
|
JP6077006B2 |
Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especiall...
|
|
JP2017025080A |
To provide pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) inhibitors effective in treatment of neurodegenerative diseases such as tauopathies including Alzheimer's disease.The invention provides pharmaceutical compo...
|
|
JPWO2014123203A1 |
Provision of a pharmaceutically excellent compound having PTP-1B inhibitory activity or a pharmaceutically acceptable salt thereof. General formula (I):[In the formula, each symbol is synonymous with the specification. ] Or a pharmaceuti...
|
|
JP6073377B2 |
The present invention relates to new thiadiazolidinediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is invo...
|
|
JP6061949B2 |
The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of ...
|
|
JP2017002052A |
To provide compounds advantageous as β-site APP (amyloid precursor protein) cleaving enzyme inhibitors and/or for the treatment and prevention of various pathologies relating to β-amyloid ("Aβ") production.The present invention provid...
|
|
JP2016222655A |
To provide a novel amidine compound having excellent bactericidal activity and a bactericidal agent or a plant disease control agent containing the same as an active ingredient.There is provided a compound represented by the formula [I] ...
|
|
JP6051218B2 |
The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxym...
|
|
JP6050071B2 |
|
|
JP6039100B2 |
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched ...
|
|
JP6038037B2 |
The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. T...
|
|
JP6023749B2 |
In its many embodiments, the present invention provides provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds ster...
|
|
JP2016188244A |
To provide a method of inhibiting tumor growth in a mammal, by administering, to the mammal, a composition containing taurolidine, taurultam, or a biologically active derivative thereof.The composition is administered to directly contact...
|
|
JP6013403B2 |
The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, ...
|
|
JP6014154B2 |
This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-medi...
|
|
JP2016532711A |
The present invention relates to compounds of 1,3,4-oxadiazole and 1,3,4-thiadiazole as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The present invention is also related to derivatives of...
|
|
JP6002467B2 |
|
|
JP5997710B2 |
A method of producing a compound of formula (I) or a pharmacologically acceptable salt thereof, useful as a therapeutic agent and/or a preventive agent for pain or for a sodium channel associated disease: Ar 1 and Ar 2 : a heteroaryl gro...
|
|
JP5995230B2 |
To provide a new organic semiconductor material comprising a compound containing azulene as a narrow band gap material which has a long wavelength absorption property and provides high charge mobility in a small molecule system, and also...
|
|
JP5991766B2 |
Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of ma...
|
|
JP5990287B2 |
The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.
|
